{'fraction_non_alphanumeric': 0.02373887240356083, 'fraction_numerical': 0.0, 'mean_word_length': 5.887755102040816, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Association of cerebrospinal fluid and plasma biomarkers with longitudinal tau accumulation

Due to its tight relation with neurodegeneration and cognitive decline, tau pathology is increasingly recognized as an attractive therapeutic target in Alzheimer’s disease. To be more efficient, clinical trials testing anti‐tau drugs need to target subjects at risk for longitudinal tau accumulation. So far, only elevated signal in an amyloid‐β (Aβ) PET scan has been consistently identified as predictor of future tau burden. Here, we studied whether more accessible cerebrospinal fluid (CSF) and plasma biomarkers were associated with PET‐measured longitudinal tau accumulation.